Marketing Authorisation Withdrawn
On 2 March, 2018, the European Medicines Agency (EMA) published a statement regarding daclizumab (Zinbryta) in adult patients for the treatment of relapsing forms of multiple sclerosis.
Subsequently, the manufacturer, Biogen have voluntarily withdrawn the marketing authorization.
- Medicine name:
- daclizumab (Zinbryta)
- SMC ID:
- In adult patients for the treatment of relapsing forms of multiple sclerosis.
- Pharmaceutical company
- Biogen Idec Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 10 April 2017